These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 28729035)

  • 1. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement factor H-related hybrid protein deregulates complement in dense deposit disease.
    Chen Q; Wiesener M; Eberhardt HU; Hartmann A; Uzonyi B; Kirschfink M; Amann K; Buettner M; Goodship T; Hugo C; Skerka C; Zipfel PF
    J Clin Invest; 2014 Jan; 124(1):145-55. PubMed ID: 24334459
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zipfel PF; Wiech T; Stea ED; Skerka C
    J Am Soc Nephrol; 2020 Feb; 31(2):241-256. PubMed ID: 31980588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement factor H related proteins (CFHRs).
    Skerka C; Chen Q; Fremeaux-Bacchi V; Roumenina LT
    Mol Immunol; 2013 Dec; 56(3):170-80. PubMed ID: 23830046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.
    Valoti E; Alberti M; Tortajada A; Garcia-Fernandez J; Gastoldi S; Besso L; Bresin E; Remuzzi G; Rodriguez de Cordoba S; Noris M
    J Am Soc Nephrol; 2015 Jan; 26(1):209-19. PubMed ID: 24904082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
    Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
    J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.
    Osborne AJ; Breno M; Borsa NG; Bu F; Frémeaux-Bacchi V; Gale DP; van den Heuvel LP; Kavanagh D; Noris M; Pinto S; Rallapalli PM; Remuzzi G; Rodríguez de Cordoba S; Ruiz A; Smith RJH; Vieira-Martins P; Volokhina E; Wilson V; Goodship THJ; Perkins SJ
    J Immunol; 2018 Apr; 200(7):2464-2478. PubMed ID: 29500241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial C3 glomerulonephritis caused by a novel CFHR5-CFHR2 fusion gene.
    Xiao X; Ghossein C; Tortajada A; Zhang Y; Meyer N; Jones M; Borsa NG; Nester CM; Thomas CP; de Córdoba SR; Smith RJ
    Mol Immunol; 2016 Sep; 77():89-96. PubMed ID: 27490940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome.
    Józsi M; Reuter S; Nozal P; López-Trascasa M; Sánchez-Corral P; Prohászka Z; Uzonyi B
    Immunol Lett; 2014 Aug; 160(2):163-71. PubMed ID: 24491679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding of the human complement regulators CFHR1 and factor H by streptococcal collagen-like protein 1 (Scl1) via their conserved C termini allows control of the complement cascade at multiple levels.
    Reuter M; Caswell CC; Lukomski S; Zipfel PF
    J Biol Chem; 2010 Dec; 285(49):38473-85. PubMed ID: 20855886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel CFHR5 fusion protein causes C3 glomerulopathy in a family without Cypriot ancestry.
    Medjeral-Thomas N; Malik TH; Patel MP; Toth T; Cook HT; Tomson C; Pickering MC
    Kidney Int; 2014 Apr; 85(4):933-7. PubMed ID: 24067434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement and glomerular disease: new insights.
    Pickering M; Cook HT
    Curr Opin Nephrol Hypertens; 2011 May; 20(3):271-7. PubMed ID: 21422921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human factor H-related protein 2 (CFHR2) regulates complement activation.
    Eberhardt HU; Buhlmann D; Hortschansky P; Chen Q; Böhm S; Kemper MJ; Wallich R; Hartmann A; Hallström T; Zipfel PF; Skerka C
    PLoS One; 2013; 8(11):e78617. PubMed ID: 24260121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
    Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
    Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal disease in the C3 glomerulopathies and the risk of impaired vision.
    Savige J; Amos L; Ierino F; Mack HG; Symons RC; Hughes P; Nicholls K; Colville D
    Ophthalmic Genet; 2016 Dec; 37(4):369-376. PubMed ID: 26915021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome.
    Sartz L; Olin AI; Kristoffersson AC; Ståhl AL; Johansson ME; Westman K; Fremeaux-Bacchi V; Nilsson-Ekdahl K; Karpman D
    J Immunol; 2012 Feb; 188(4):2030-7. PubMed ID: 22250080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overactivity of Alternative Pathway Convertases in Patients With Complement-Mediated Renal Diseases.
    Michels MAHM; van de Kar NCAJ; Okrój M; Blom AM; van Kraaij SAW; Volokhina EB; van den Heuvel LPWJ
    Front Immunol; 2018; 9():612. PubMed ID: 29670616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.